<h4>Background</h4>Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, which limits the availability of targeted therapies and results in poor prognosis. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.